BioSpace News Archive

Sensorion announces that its management team, including CEO Nawal Ouzren and CBO Juergen Heitmann, will be present in San Francisco, USA, during the 38th annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2020.

QIAGEN N.V. announced that it plans as previously announced to release its report on results for the fourth quarter and full-year 2019 on Tuesday, February 4, at approximately 22:05 Central European Time / 16:05 Eastern Standard Time..

IDEAYA Biosciences, Inc. announced that the company has entered into a Sponsored Research Agreement with Boston Children’s Hospital for preclinical evaluation of the role of protein kinase C in Sturge Weber syndrome, a rare neurocutaneous disorder characterized by capillary malformations and associated with mutations in GNAQ.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients today announced a research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to further develop LB-301, an investigational therapy using LogicBio’s proprietary, promoterless, nuclease-free genome editing technology, GeneRide™, for the treatment of Crigler-Najjar syndrome.

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (Nasdaq: NEPT) (TSX: NEPT), a health and wellness company focused on extraction, purification and formulation of cannabinoids, would like to provide the following corporate updates and outlook ahead of its participation at the Annual ICR Conference in Orlando, Florida

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical development and early clinical studies.

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces unaudited preliminary revenue for the fourth quarter and full year 2019.

Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing pro-drugs to enable the promise of potent immune-activating biotherapeutics in solid tumors, today announced that it has provided a technology license to F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”) to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets

Transplant Genomics, Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics, today announced that Dr. John Holman has joined the Company as VP Medical Affairs. Dr. Holman comes to TGI having served for the past two years as VP, Immunology and Translational Medicine, at Quark Pharmaceuticals.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will host and webcast an investor briefing at the North American Neuromodulation Society (NANS 2020) in Las Vegas, NV on Saturday, January 25, 2020, beginning at 3:00 p.m. PST